BBLG: Back Pain Solution Potentially on the Way By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Benzinga · Feb 24, 2022
DYAI: Don't Put All Your Eggs in One Basket By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Benzinga · Feb 22, 2022
ALVOF: Alvopetro Energy's Organic Growth Plan Continues to be Successfully Executed. Production continues to grow and contract pricing significantly increased effective February 1st. By Steven Ralston, CFA OTC:ALVOF | TSX:ALV.V READ THE FULL ALVOF RESEARCH REPORT Benzinga · Feb 17, 2022
UHAL: AMERCO reports another strong quarter with revenues above expectations. Adjusted for seasonality of the company's businesses, UHAL continues to experience robust demand and strong pricing in the current environment. By Steven Ralston, CFA NASDAQ:UHAL READ THE FULL UHAL RESEARCH REPORT Benzinga · Feb 15, 2022
BTCY: Initiating Coverage – Outpatient Remote Cardiac Health Monitoring & Ecosystem with Emerging Growth Company Profile By T. Moore, CFA NASDAQ:BTCY READ THE FULL BTCY RESEARCH REPORT Benzinga · Feb 10, 2022
UCASU: Diversification into agriculture properties continues By Beth Senko, CFA OTC:UCASU READ THE FULL UCASU RESEARCH REPORT Benzinga · Feb 7, 2022
SQZ: IND Cleared for Enhanced APCs By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT Benzinga · Feb 7, 2022
ACHV: The Final Phase III Begins By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Benzinga · Feb 4, 2022
Why The Stock Market Is 'Not Out Of The Woods Yet' Cameron Dawson, CFA and chief market strategist at Fieldpoint Private, joined Benzinga’s PreMarket Prep show Tuesday morning. Benzinga · Feb 1, 2022
BIOAF: Third Quarter Results By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT Benzinga · Jan 31, 2022
BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Benzinga · Jan 31, 2022
LGVN: Using Cellular Technology to Ease Major Medical Issues By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Benzinga · Jan 26, 2022
DRIO: 2022 Outlook, Physimax Acquisition By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Benzinga · Jan 24, 2022
Nation records highest death toll for the pandemic following grim two weeks of rising numbers – as it happened This blog is now closed The Guardian - AU · Jan 20, 2022
Benzinga · Jan 20, 2022 MDXG: Model Updates By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT
Benzinga · Jan 20, 2022 LTRN: Multiple Collaborations Illuminating Way Forward By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT
Benzinga · Jan 13, 2022 HTBX: RapidVax Unveiled; Elusys Acquisition By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT
Benzinga · Jan 13, 2022 EMMA: Easing Suffering from Sickle Cell Disease By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT